Business Description
Prime Medicine Inc
NAICS : 541714
SIC : 2833
ISIN : US74168J1016
Total Employee Number:
146Description
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.18 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 1.49 | |||||
Debt-to-EBITDA | -0.58 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.54 | |||||
Beneish M-Score | -4.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 26.3 | |||||
3-Year EPS without NRI Growth Rate | 30 | |||||
3-Year FCF Growth Rate | 36.4 | |||||
3-Year Book Growth Rate | -41 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.07 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.71 | |||||
9-Day RSI | 62.59 | |||||
14-Day RSI | 57.64 | |||||
3-1 Month Momentum % | -18.41 | |||||
6-1 Month Momentum % | -15.14 | |||||
12-1 Month Momentum % | 12.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 3.8 | |||||
Cash Ratio | 3.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.9 | |||||
Shareholder Yield % | -9.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5121.77 | |||||
Net Margin % | -4917.55 | |||||
EBITDA Margin % | -4936.42 | |||||
FCF Margin % | -3935.05 | |||||
OCF Margin % | -3877.47 | |||||
ROE % | -188.15 | |||||
ROA % | -60.86 | |||||
ROIC % | -113.88 | |||||
3-Year ROIIC % | -89.07 | |||||
ROC (Joel Greenblatt) % | -142.85 | |||||
ROCE % | -71.12 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 127.04 | |||||
PB Ratio | 8.07 | |||||
Price-to-Tangible-Book | 7.98 | |||||
EV-to-EBIT | -2.9 | |||||
EV-to-EBITDA | -3.01 | |||||
EV-to-Revenue | 148.37 | |||||
EV-to-Forward-Revenue | 23.54 | |||||
EV-to-FCF | -3.77 | |||||
Earnings Yield (Greenblatt) % | -34.48 | |||||
FCF Yield % | -25.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRME
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prime Medicine Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.034 | ||
| EPS (TTM) ($) | -1.25 | ||
| Beta | 3.1166 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 143.46 | ||
| 14-Day RSI | 57.64 | ||
| 14-Day ATR ($) | 0.277484 | ||
| 20-Day SMA ($) | 3.12375 | ||
| 12-1 Month Momentum % | 12.08 | ||
| 52-Week Range ($) | 2.28 - 6.94 | ||
| Shares Outstanding (Mil) | 180.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prime Medicine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prime Medicine Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 40 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 10:40 | 2.88 (-3.68%) | ||
| General meeting for 2026 | 2026-06-05 14:00 | 3.47 (+9.46%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 12:50 | 3.14 (-3.98%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.41 (-1.16%) | ||
| The Citizens Life Sciences Conference | 2026-03-11 14:15 | 4.05 (-2.64%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 13:10 | 4.23 (-5.16%) | ||
| Annual report for 2025 | 2026-03-03 | 4.66 (+5.91%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-03 | 4.66 (+5.91%) |
Show
Entries
Prime Medicine Inc Frequently Asked Questions
What is Prime Medicine Inc(PRME)'s stock price today?
The current price of PRME is $3.43. The 52 week high of PRME is $6.94 and 52 week low is $2.28.
When is next earnings date of Prime Medicine Inc(PRME)?
The next earnings date of Prime Medicine Inc(PRME) is 2026-08-07 Est..
Does Prime Medicine Inc(PRME) pay dividends? If so, how much?
Prime Medicine Inc(PRME) does not pay dividend.
Guru Commentaries on NAS:PRME
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm | 2025-01-30 | ||
| Prime Medicine Announces Pricing of Upsized Initial Public Offering | 2022-10-19 |
Articles on Prime Medicine Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers